Provided By GlobeNewswire
Last update: Jun 25, 2024
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity.
NASDAQ:DRTS (6/26/2025, 1:57:11 PM)
3.02
+0.02 (+0.67%)
NASDAQ:DRTSW (6/26/2025, 1:48:19 PM)
0.2498
0 (-0.04%)
Find more stocks in the Stock Screener